Our Company
HEC Pharm USA Inc was established in 2011 and incorporated in the state of New Jersey with a current office location in Philadelphia area, Pennsylvania.
At A Glance
HEC Pharm was established in 2002. After several years development, HEC Pharm has become one of the most innovative and promising pharmaceutical companies in China, here are some mainly achievements:
In 2006, HEC was granted a license from Roche to produce oseltamivir in China. HEC Pharm, now is the largest manufacturer in China of oseltamivir, and its trade name, Kewei.
In 2008, HEC Pharm became the largest and most advanced manufacturing base for the highest quality macrolides production in the world. Our client list includes global corporations such as Pfizer and Abbott Laboratories.
HEC Pharm also established a premier sales force in China. We now have more than 213 domestic sales offices which include 1,500 medical representatives with that number expected to expand to 3,000 by 2017. At the same time our sales team operates overseas branches in the United Stated, Germany, Japan and Australia.
Our Company
Fast Growing Pharma Company
HEC Pharm USA is a company owned and supported by HEC Pharm, one of the top 50 private enterprises in China located in Shenzhen, China. As a U.S.-based subsidiary of HEC Group, HEC Pharm USA represents HEC Group on communicating with FDA and doing Business Development. In researching and developing to expand treatment options, HEC Pharm USA continually aims to improve the quality of its products and services.
Therapeutic Areas of Focus
Medicine for everyone
Our mission is shaped in the light of ethical standards and social responsibility, high quality and environmental awareness. Commitment by all areas of the company our motto is lived. For the implementation of our mission, we attach particular importance to:
- – Continuous improvement of the quality of our products and services
- – The satisfaction of patient and customer always first
- – Our special responsibility for the environment and society
- – Research and development to expand the treatment options
